Ірландія - англійська - HPRA (Health Products Regulatory Authority)

zoetis ireland limited - spectinomycin (as spectinomycin sulphate ph.eur.), lincomycin (as lincomycin hydrochloride ph. eur.) - powder for oral solution - 222/444.7 - lincomycin, combinations - fowl - chicken, porcine - antibacterial

США - англійська - NLM (National Library of Medicine)

pharmacia & upjohn company llc - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - lincomycin 300 mg in 1 ml - lincocin is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of cdad, as described in the boxed warning , before selecting lincomycin the physician should consider the nature of the infection and the suitability of other alternatives. indicated surgical procedures should be performed in conjunction with antibacterial therapy. lincocin may be administered concomitantly with other antimicrobial agents when indicated. lincocin is not indicated in the treatment of minor bacterial infections or viral infections. to reduce the development of drug-resistant bacteria and maintain the effectiveness of lincocin and other antibacterial drugs, lincocin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - lincomycin hydrochloride monohydrate, quantity: 680.4 mg (equivalent: lincomycin, qty 600 mg) - injection, solution - excipient ingredients: benzyl alcohol; water for injections - lincomycin lws is indicated in the treatment of serious infections due to susceptible strains of gram-positive aerobes such as streptococci, pneumococci and staphylococci.,its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. because of the risk of colitis (see precautions), before selecting lincomycin the physician should consider the nature of infection and the suitability of less toxic alternatives (e.g. erythromycin).,lincomycin injection has been demonstrated to be effective in the treatment of staphylococcal infections resistant to other antibiotics and susceptible to lincomycin. staphylococcal strains resistant to lincomycin injection have been recovered; culture and susceptibility studies should be done in conjunction with lincomycin injection therapy. in the case of macrolides, partial but not complete cross resistance may occur. the drug may be administered concomitantly with other antimicrobial agents with which it is compatible when indicated (see precautions).,the specific infections for which lincomycin lws is indicated are as follows:,upper respiratory infections including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet fever and as adjuvant therapy for diphtheria. effectiveness in the treatment of mastoiditis would be anticipated.,lower respiratory infections including acute and chronic bronchitis and pneumonia.,skin and skin structure infections including cellulitis, furuncles, abscesses, impetigo, acne and wound infections. conditions such as erysipelas, lymphadenitis, paronychia (panaritium), mastitis and cutaneous gangrene should, if caused by susceptible organisms, respond to lincomycin therapy.,bone and joint infections including osteomyelitis and septic arthritis.,septicaemia and endocarditis. selected cases of septicaemia and/or endocarditis due to susceptible organisms have responded well to lincomycin. however, bactericidal drugs are often preferred for these infections.,bacillary dysentery. although shigella is resistant to lincomycin in vitro (mic approximately 200-400 micrograms/ml), lincomycin has been effective in its treatment due to the very high levels of lincomycin attained in the bowel (approximately 3000-7000 micrograms/gram of stool).

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - lincomycin hydrochloride monohydrate, quantity: 340.2 mg (equivalent: lincomycin, qty 300 mg/ml) - injection, solution - excipient ingredients: benzyl alcohol; water for injections - lincomycin lws is indicated in the treatment of serious infections due to susceptible strains of gram-positive aerobes such as streptococci, pneumococci and staphylococci.,its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. because of the risk of colitis (see precautions), before selecting lincomycin the physician should consider the nature of infection and the suitability of less toxic alternatives (e.g. erythromycin).,lincomycin injection has been demonstrated to be effective in the treatment of staphylococcal infections resistant to other antibiotics and susceptible to lincomycin. staphylococcal strains resistant to lincomycin injection have been recovered; culture and susceptibility studies should be done in conjunction with lincomycin injection therapy. in the case of macrolides, partial but not complete cross resistance may occur. the drug may be administered concomitantly with other antimicrobial agents with which it is compatible when indicated (see precautions).,the specific infections for which lincomycin lws is indicated are as follows:,upper respiratory infections including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet fever and as adjuvant therapy for diphtheria. effectiveness in the treatment of mastoiditis would be anticipated.,lower respiratory infections including acute and chronic bronchitis and pneumonia.,skin and skin structure infections including cellulitis, furuncles, abscesses, impetigo, acne and wound infections. conditions such as erysipelas, lymphadenitis, paronychia (panaritium), mastitis and cutaneous gangrene should, if caused by susceptible organisms, respond to lincomycin therapy.,bone and joint infections including osteomyelitis and septic arthritis.,septicaemia and endocarditis. selected cases of septicaemia and/or endocarditis due to susceptible organisms have responded well to lincomycin. however, bactericidal drugs are often preferred for these infections.,bacillary dysentery. although shigella is resistant to lincomycin in vitro (mic approximately 200-400 micrograms/ml), lincomycin has been effective in its treatment due to the very high levels of lincomycin attained in the bowel (approximately 3000-7000 micrograms/gram of stool).

США - англійська - NLM (National Library of Medicine)

aspen veterinary resources - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - indications for swine: lincomycin 300 is indicated for the treatment of infectious forms of arthritis caused by organisms sensitive to its activity. this includes most of the organisms responsible for the various infectious arthritides in swine, such as staphylococci, streptococci, erysipelothrix and mycoplasma spp. it is also indicated for the treatment of mycoplasma pneumonia. contraindications: as with all drugs, the use of lincomycin 300 is contraindicated in animals previously found to be hypersensitive to the drug. human warnings: not for human use. keep out of reach of children.

Велика Британія - англійська - VMD (Veterinary Medicines Directorate)

laboratorios maymo s.a. - lincomycin, spectinomycin - powder for use in drinking water - antimicrobial - pigs

Канада - англійська - Health Canada

bio agri mix lp - lincomycin (lincomycin hydrochloride); spectinomycin (spectinomycin hydrochloride) - powder for solution - 33.3g; 66.6g - lincomycin (lincomycin hydrochloride) 33.3g; spectinomycin (spectinomycin hydrochloride) 66.6g - swine (pigs); poultry

США - англійська - NLM (National Library of Medicine)

a-s medication solutions - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - lincomycin injection, usp is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of cdad, as described in the boxed warning , before selecting lincomycin the physician should consider the nature of the infection and the suitability of other alternatives. indicated surgical procedures should be performed in conjunction with antibacterial therapy. lincomycin injection may be administered concomitantly with other antimicrobial agents when indicated. lincomycin is not indicated in the treatment of minor bacterial infections or viral infections. to reduce the development of drug-resistant bacteria and maintain the effectiveness of lincomycin and other antibacterial drugs, lincomycin should be used only to treat or prevent infections that are proven or strongly suspected

Австралія - англійська - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - lincomycin as lincomycin hydrochloride - unknown - lincomycin as lincomycin hydrochloride antibiotic active 0.0 - active constituent

Австралія - англійська - APVMA (Australian Pesticides and Veterinary Medicines Authority)

abbey laboratories pty ltd - lincomycin hydrochloride - unknown - lincomycin hydrochloride antibiotic active 0.0 - active constituent